Therapeutic drug monitoring for imatinib: Current status and Indian experience
Imatinib is the current gold standard for treatment of chronic myeloid leukemia (CML). Recent pharmacokinetic studies have shown considerable variability in trough concentrations of imatinib due to variations in its metabolism, poor compliance, or drug-drug interactions and highlighted its impact on...
Saved in:
| Main Authors: | Brijesh Arora, Vikram Gota, Hari Menon, Manju Sengar, Reena Nair, Pankaj Patial, S D Banavali |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2013-01-01
|
| Series: | Indian Journal of Medical and Paediatric Oncology |
| Subjects: | |
| Online Access: | http://www.ijmpo.org/article.asp?issn=0971-5851;year=2013;volume=34;issue=3;spage=224;epage=228;aulast=Arora |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Chronic myeloid leukemia — before and after imatinib (Third part)
by: E. G. Lomaia, et al.
Published: (2022-11-01) -
The Role of STAT5 in Tyrosine Kinase Inhibitor (IMATINIB) Resistance in CML Patients
by: Anastasia Putri, et al.
Published: (2020-02-01) -
The Role of STAT5 in Tyrosine Kinase Inhibitor (IMATINIB) Resistance in CML Patients
by: Anastasia Putri, et al.
Published: (2020-02-01) -
Imatinib mesylate resistance and mutations: An Indian experience
by: Shweta Srivastava, et al.
Published: (2013-01-01) -
The role of mutation testing in patients with chronic myeloid leukemia in chronic phase after imatinib failure and their outcomes after treatment modification: Single-institutional experience over 13 years
by: Puligundla Krishna Chaitanya, et al.
Published: (2017-01-01)